RhumbLine Advisers
RVMD icon

RhumbLine Advisers’s Revolution Medicines RVMD Stock Holding History

RhumbLine Advisers’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3M Buy
226,008
+46,066
+26% +$6.73M 0.03% 442
2026
Q1 		$17.5M Buy
179,942
+19,494
+12% +$1.97M 0.02% 774
2025
Q4 		$12.8M Buy
160,448
+6,634
+4% +$435K 0.01% 950
2025
Q3 		$7.18M Sell
153,814
-2,777
-2% -$109K 0.01% 1241
2025
Q2 		$5.76M Sell
156,591
-100,559
-39% -$3.86M ﹤0.01% 1334
2025
Q1 		$9.09M Buy
257,150
+5,685
+2% +$231K 0.01% 1056
2024
Q4 		$11M Buy
251,465
+24,473
+11% +$1.24M 0.01% 1004
2024
Q3 		$10.3M Sell
226,992
-1,575
-0.7% -$68.6K 0.01% 1033
2024
Q2 		$8.87M Buy
228,567
+19,257
+9% +$720K 0.01% 1084
2024
Q1 		$6.75M Buy
209,310
+3,952
+2% +$117K 0.01% 1258
2023
Q4 		$5.89M Buy
205,358
+59,786
+41% +$1.44M 0.01% 1316
2023
Q3 		$4.03M Buy
145,572
+6,894
+5% +$204K ﹤0.01% 1477
2023
Q2 		$3.71M Buy
138,678
+5,263
+4% +$129K ﹤0.01% 1560
2023
Q1 		$2.89M Buy
133,415
+14,678
+12% +$361K ﹤0.01% 1619
2022
Q4 		$2.83M Buy
118,737
+10,635
+10% +$226K ﹤0.01% 1612
2022
Q3 		$2.13M Buy
108,102
+17,199
+19% +$378K ﹤0.01% 1726
2022
Q2 		$1.77M Buy
90,903
+14,960
+20% +$291K ﹤0.01% 1828
2022
Q1 		$1.94M Sell
75,943
-4,113
-5% -$89.5K ﹤0.01% 1831
2021
Q4 		$2.02M Sell
80,056
-754
-0.9% -$21.3K ﹤0.01% 1880
2021
Q3 		$2.22M Buy
80,810
+2,609
+3% +$75.9K ﹤0.01% 1852
2021
Q2 		$2.48M Buy
78,201
+32,407
+71% +$1.13M ﹤0.01% 1841
2021
Q1 		$2.1M Sell
45,794
-533
-1% -$23.9K ﹤0.01% 1882
2020
Q4 		$1.83M Buy
46,327
+4,799
+12% +$190K ﹤0.01% 1890
2020
Q3 		$1.45M Buy
41,528
+22,719
+121% +$629K ﹤0.01% 1845
2020
Q2 		$594K Buy
18,809
+4,487
+31% +$141K ﹤0.01% 2268
2020
Q1 		$314K Buy
+14,322
New +$396K ﹤0.01% 2383

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RhumbLine Advisers's RVMD Position: Q2 2026 in Review

RhumbLine Advisers increased its Revolution Medicines (RVMD) stake by 26% in Q2 2026, buying an estimated $6.73M and bringing the position to 226,008 shares worth $42.3M. The position accounts for 0.03% of the portfolio, ranked #442.

RhumbLine Advisers first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • RhumbLine Advisers held 226,008 shares of Revolution Medicines worth $42.3M as of Q2 2026.
  • RhumbLine Advisers bought 46,066 Revolution Medicines shares in Q2 2026, an estimated $6.73M.
  • Revolution Medicines made up 0.03% of RhumbLine Advisers's portfolio in Q2 2026, its #442 holding.
  • RhumbLine Advisers first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.